Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adient plcADNT · Entity 4713 | Director | March 10, 2026 | March 12, 2026 |
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | SVP, Chief Info & Digital Off. | April 01, 2022 | April 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adient plc
Report date March 10, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 24,551 |
Reported balance
After 2026-03-10 transaction · row 1
1 source rowRow 1 · 2026-03-10 · Grant · Acquired 8,208 · Balance 24,551 F1: Shares delivered as compensation for service as a director under the Adient plc 2021 Omnibus Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares delivered as compensation for service as a director under the Adient plc 2021 Omnibus Incentive Plan.
BOSTON SCIENTIFIC CORP
Report date April 01, 2022 · Filed April 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,263 |
Reported balance
After 2022-04-01 transaction · row 1
1 source rowRow 1 · 2022-04-01 · Sale · Disposed 2,779 · Balance 23,263 F1: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2019 Filed Jan 3, 2019 21:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,099 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000446 · doc4.xml · derivative · entry 3 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,099 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on January 2, 2015, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on January 2, 2015, the first anniversary of the date of grant. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 730 | $34.46 | $25,155.80 |
DisclosureSEC source: 0001225208-19-000446 · doc4.xml · nonDerivative · entry 2 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,560 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,099 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000446 · doc4.xml · nonDerivative · entry 1 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.